Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Last updated: January 31, 2019
Sponsor: Psoriasis Treatment Center of Central New Jersey
Overall Status: Active - Recruiting

Phase

4

Condition

Rash

Scalp Disorders

Warts

Treatment

N/A

Clinical Study ID

NCT03827876
PTC04
  • Ages > 18
  • All Genders

Study Summary

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female adult ≥ 18 years of age;

  • Diagnosis of chronic plaque-type

  • Patient with 2-10% BSA

  • Physician Global Assessment of 2 or greater

  • Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

Exclusion

Exclusion Criteria:

  • ˂2 or >10% BSA

  • PGA <2

  • Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab <24weeks

Study Design

Total Participants: 30
Study Start date:
January 16, 2019
Estimated Completion Date:
December 15, 2019

Study Description

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

Connect with a study center

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey 08520
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.